Comparison of weekly and 3-weekly schedule of docetaxel as second line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data from 818 patients

被引：0
|
作者：
Di Maio, M.
Perrone, F.
Chiodini, P.
Gallo, C.
Camps, C.
Quoix, E.
Schuette, W.
Gridelli, C.
机构：
[1] Ist Nazl Tumori, Unita Sperimentaz Clin, Naples, Italy
[2] Seconda Univ Napoli, Dipartimento Med Pubbl Clin & Prevent, Naples, Italy
[3] Hosp Gen Univ, Valencia, Spain
[4] Hop Lyautey, Strasbourg, France
[5] Martha Maria City Hosp Halle Doelau, Halle, Germany
[6] Azienda Osped S Giuseppe Moscati, Avellino, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI25 / XI25
页数：1
相关论文
共 50 条
  • [31] Single agent vs combination chemotherapy (CT) as second-line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data of five randomized trials
    Di Maio, M.
    Chiodini, P.
    Georgoulias, V.
    Hatzidaki, D.
    Takeda, K.
    Wachters, F. M.
    Gebbia, V.
    Morabito, A.
    Perrone, F.
    Gridelli, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)
    Sovak, M. A.
    Lutzker, S.
    Guensch, L.
    Joyce, M.
    Schwartz, S.
    Wu, Y.
    Zheng, L.
    Aisner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients The DISTAL-2 randomized trial
    Gebbia, Vittorio
    Gridelli, Cesare
    Verusio, Claudio
    Frontini, Luciano
    Aitini, Enrico
    Daniele, Bruno
    Gamucci, Teresa
    Mancuso, Gianfranco
    Di Maio, Massimo
    Gallo, Ciro
    Perrone, Francesco
    Morabito, Alessandro
    LUNG CANCER, 2009, 63 (02) : 251 - 258
  • [34] Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study.
    Schuette, W
    Nagel, S
    Serke, M
    Lautenschlaeger, C
    Hans, K
    Lorenz, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
  • [35] Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial
    Serke, M
    Schoenfeld, N
    Loddenkemper, R
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1211 - 1216
  • [36] Meta-analysis of weekly paclitaxel as maintenance therapy for advanced non-small cell lung cancer (NSCLC) patients following intitial chemotherapy
    Belani, C
    Barstis, J
    LaRocca, R
    Tester, W
    Gable, P
    Perry, M
    Ramalingam, S
    LUNG CANCER, 2005, 49 : S33 - S33
  • [37] Weekly vs three-weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC): updated results of a randomized Phase III study
    Schuelle, Wolfgang
    Nagel, Silke
    Serke, Monika
    Lautenschlaeger, Christine
    Hans, Klaus
    Lorenz, Christine
    ANNALS OF ONCOLOGY, 2004, 15 : 167 - 168
  • [38] Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: A meta-analysis
    Rakovitch, E
    Tsao, M
    Ung, Y
    Pignol, JP
    Cheung, P
    Chow, E
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (01): : 196 - 203
  • [39] Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer
    Syrios, John
    Nintos, Georgios
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (08) : 875 - 884
  • [40] Cisplatin plus docetaxel as second-line treatment in metastatic non-small-cell lung cancer (NSCLC)
    Doria, Simona
    Prochilo, Tiziana
    Cafferata, Mara Argenide
    Tiseo, Marcello
    Ardizzoni, Andrea
    Baldini, Editta
    ANNALS OF ONCOLOGY, 2007, 18 : 28 - 29
12345